Published in final edited form as:

Sex Med Rev. 2019 April; 7(2): 202–222. doi:10.1016/j.sxmr.2018.12.001.

#### Sexual function in women with colorectal/anal cancer

Jocelyn Canty, MA<sup>1</sup>, Cara Stabile, MPH<sup>2</sup>, Lisania Milli, NP<sup>3</sup>, Barbara Seidel, NP<sup>3</sup>, Deborah Goldfrank, MD<sup>1,4</sup>, and Jeanne Carter, PhD<sup>1,5</sup>

<sup>1</sup>Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>2</sup>Plastic and Reconstructive Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>3</sup>Nursing, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>4</sup>Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY

<sup>5</sup>Department of Psychology, Weill Cornell Medical College, New York, NY

#### **Abstract**

**Introduction:** Treatments for colorectal and anal cancers can have a detrimental impact on sexual function. Type of treatment, which may include surgery, radiation and/or chemotherapy, varies by disease site and severity. Treatment and long-term side effects can impact sexual function and intimacy for patients and their partners.

**Aim:** To review the literature regarding treatment for colorectal/anal cancer and its impact on female sexual function, and to provide an assessment of medical outcomes and patient-reported outcomes (PROs) of women with a history of colon, rectal, or anal cancer seeking sexual health treatment.

**Methods:** We performed a PubMed search to identify peer-reviewed, English-language articles, published from 2008 to 2018, using the following search terms: "colorectal cancer," or "rectal cancer," or "anal cancer" and "sexual function," or "sexual dysfunction." We also assessed the medical outcomes and PROs from our recent cross-sectional cohort study of 99 women with a history of colon, rectal, or anal cancer seeking sexual health treatment.

**Main Outcome Measures:** Sexual function, quality of life, and PROs after colorectal/anal cancer

**Results:** Twenty-three studies were identified. Study designs included 15 cross-sectional survey studies, 5 longitudinal studies, 2 psychoeducational interventions, and 1 pilot study. Ten studies included women and 13 included both men and women. The literature and our cohort confirmed

Corresponding author: Jeanne Carter, PhD, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, Tel. 646-888-5076, carterj@mskcc.org.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

that women with colorectal/anal cancer experience changes in sexual function after diagnosis and through the continuum of care. The scarcity of data in this area, however, indicates a need for additional intervention trials and longitudinal studies.

**Conclusions:** Research studies with large sample sizes and long study durations are needed to help us better understand the needs of female survivors of colorectal/anal cancer. Women with colorectal/anal cancer need simple strategies and resources to address concerns of sexual function after cancer treatment. Such interventions have been shown to enhance survivorship and quality of life.

#### Keywords

colorecta	l cancer;	anal can	er; sexu	al heal	lth;	femal	e; su	rvivorsl	nip		

#### Introduction

The U.S. population of cancer survivors is expected to grow to 20 million by 2026 [1]. Despite early screening/detection and cancer prevention strategies, colorectal cancer is a common malignancy among both men and women [2]. Anal cancer is less common; however, the number of newly diagnosed anal cancer cases is rising every year [3]. The incidence and mortality rates of colorectal cancer are higher in men than in women, and rates of anal cancer are slightly higher in women [3]. In 2018, there will be an estimated 47,530 newly diagnosed cases of colon cancer, 17,100 new cases of rectal cancer, and 5,620 new cases of anal cancer among women [4].

Treatment for colorectal/anal cancers varies by disease site and severity. Standard treatment typically includes a combination of surgery, chemotherapy, and/or radiation therapy.

Management of colorectal cancer relies primarily on surgical resection of the bowel with the adjacent draining lymph nodes. The use of neoadjuvant or adjuvant chemotherapy (with or without radiation) to treat colorectal cancer depends on tumor location and disease stage. Treatment for colorectal/anal cancer may require a temporary or permanent stoma (an artificial opening on the abdomen through which the bowel or bladder diverts). The stoma opening allows for the attachment of a changeable bag through which feces can be eliminated [5]. For anal cancer, primary radical radiotherapy and concomitant chemotherapy improves survival while also preserving the anal sphincter [6]. Five-year survival rates for colorectal/anal cancer have improved in recent years with screening advancements, an increase in the removal of colonic polyps (precursors to cancer), novel surgical techniques and therapies (adjuvant therapy), better preoperative staging, and targeted therapies [7]. The use of adjuvant chemotherapy for colon cancer and neoadjuvant chemoradiation for rectal cancer has also improved survival rates [8].

Female survivors of colorectal/anal cancer are typically older adults, with an average age of 72 for colon, 63 for rectal, and early 60s for anal cancer [1]. Common issues of aging, such as comorbid illnesses and vulvovaginal tissue quality, can be exacerbated by cancer therapy [7]. As these women live longer, understanding the long-term side effects of treatment are a priority.

Common physical side effects of treatment include autonomic nerve injury, bowel function issues (incontinence, increased stool frequency, flatulence), buttock pain, and vulvovaginal health issues (dryness, fibrosis, adhesions, shortening) [9–11], all of which can adversely impact quality of life (QOL). Colorectal/anal cancer can have adverse and persisting effects on sexual function and psychological wellbeing. It should be noted that urological issues such as erectile dysfunction are common among male cancer survivors and can result in significant difficulties in survivorship [12]; however in this review, we will explore the limited but recent literature on the sexual health of women diagnosed and treated for colorectal/anal cancer, as well as offer insights from our recent cohort of women who sought treatment to address vulvovaginal sexual health concerns.

#### **Methods**

#### Literature Review

We searched PubMed for peer-reviewed, English-language articles published from 2008–2018 using the following search terms: "colorectal cancer," or "rectal cancer," or "anal cancer" and "female," and "sexual function," or "sexual dysfunction." Since most of the studies we identified were not exclusively female focused, we included studies that had both male and female patients. The criteria for inclusion consisted of peer-reviewed articles (cross-sectional, longitudinal, interventional, or pilot studies) addressing sexual function in women with a history of colon, rectal, or anal cancer. The study had to incorporate the use of measures assessing sexual function. Review papers were excluded. Within the literature, the prevalence rates for specific sexual dysfunction are difficult to define, in part because of different methods for data collection and lack of baseline data on sexual activity prior to cancer treatment. All studies presented in this review used at least one validated measure.

#### Colorectal/Anal Cancer Cohort

An IRB-approved limited waiver of authorization was obtained for our recent cross-sectional cohort study. Ninety-nine women with a history of colon, rectal, or anal cancer were seen for an initial consult at the Female Sexual Medicine and Women's Health Program at Memorial Sloan Kettering Cancer Center from 01/12–07/17. A female sexual medicine clinical assessment form was used to collect medical and patient characteristics and patient-reported outcomes (PROs). The form consists of PRO measures, including the Vaginal Assessment Scale (VAS), Vulvar Assessment Scale (VuAS), Female Sexual Function Index (FSFI), Sexual Activity Questionnaire (SAQ). In addition, exploratory items addressing self-efficacy and sexual/vaginal health regarding confidence about sexual activity, using vaginal health promotion strategies, and managing sexual health/vaginal health issues in the future were included, as well as the degree of concern about sexual function and vaginal health. Medical data were obtained using a pelvic exam checklist and documentation of use of vulvovaginal/sexual health promotion strategies. Descriptive statistics were calculated using SPSS.

#### Results

#### Overview of the Literature

Of 65 initially identified studies, 23 met our inclusion criteria (Table 1) [13–35]. Of the 23 studies, 10 included women only [13–18, 23, 25, 30, 34] and 13 included both men and women [19–22, 24, 26–29, 31–33, 35]. There were 15 cross-sectional survey studies [13–15, 17, 19–21, 24–26, 30–34], 2 psychoeducational interventions [23, 27], 5 longitudinal studies [16, 18, 22, 29, 345], and 1 pilot study [28].

The most common instruments used were the EORTC-QLQ-C30 [21, 23, 25, 33, 36], the EORTC-QLQ-CR38 [13, 14, 20, 21, 24, 25, 32, 33, 37], and the FSFI [13, 15–18, 23, 24, 26–28, 30, 31, 33, 34, 38, 39]. These measures have strong reliability and validity. The FSFI asks participants to recall their sexual activity within the past 4 weeks, making it difficult to assess function when no sexual activity occurred within that time frame.

Patients who do not report any sexual function concerns before their cancer diagnosis may experience changes during or after cancer treatment [40]. An estimated 75% of patients with colorectal cancer experience sexual difficulties after treatment, and up to one-third refrain from sexual activity post-treatment regardless of physical dysfunction [28]. Sexual dysfunction is the impairment of one's typical pattern of intimate sexual response and can include changes in sexual desire, arousal, orgasm ability, pain, vaginal dryness or atrophy, as well as feeling a lack of femininity, sexual attractiveness, and confidence [24, 41–43]. Contributing factors include use of neoadjuvant or adjuvant radiation, age, tumor stage, and surgical experience and technique. Older patients tend to have pre-existing sexual changes [5, 44]. Patients undergoing nerve-sparing surgical techniques to help mitigate symptoms can still experience sexual dysfunction [45].

Though sexual and vulvovaginal health concerns after treatment for colorectal/anal cancer are prevalent, they are rarely studied. Patients with a history of colorectal/anal cancer should undergo regular follow-up and evaluation for the management of treatment-related side effects; however, the data regarding associated changes in sexual function to guide such management are limited. The existing literature is mainly retrospective, consisting of small sample sizes and mostly male patients. Furthermore, patient engagement with healthcare providers to address these issues is low [21]. Many female cancer patients and survivors have indicated that sexual matters were never discussed before or after their treatment, and many did not initiate such conversations with their healthcare providers [10]. In a study by Da Silva et al., 81% of women stated that it was somewhat-to-extremely important to discuss sexual issues with their provider [18]. Studies with cancer survivors suggest they would like to have conversations on sexuality with their medical team [46]. Additionally, many couples report a desire for candid conversations about sexual health challenges [5, 47].

Targeted interventions and resources addressing sexual and vulvovaginal health can aid women and their partners in adjusting to changes during and after treatment. Sexual health interventions have shown promising results in addressing these concerns and emphasize the need for targeted therapies for sexual/relationship satisfaction. The implications of these limited intervention trials are significant. For example, Barsky-Reese et al. and DuHammel

et al. provided evidence that it is essential to not only evaluate patient concerns but efficiently address worry/distress to enhance intimacy [23, 27]. Increased attention and considerable effort to identify and manage symptoms of colorectal/anal patients in survivorship can promote adjustment and foster realistic expectations. Findings by Park et al. suggest that the information patients receive, as well as personal attitudes, play a role in expectations for post-treatment function (e.g., bowel function) [48]. Research into the psychological, informational, and experiential components that underlie patient expectations of surgical recovery can be useful for healthcare professionals looking to develop strategies for proactive patient education [48]. Recording quantitative outcomes and qualitative findings post treatment may reveal symptomatic trends that can be discussed by healthcare professionals in early clinical conversations and monitored throughout survivorship [48]. Additionally, setting realistic expectations on post-treatment function can help healthcare professionals and patients work together to manage symptoms throughout the continuum of cancer care.

Some patients may require either a temporary or permanent stoma after colorectal surgery. For these patients, having sufficient information and support around stoma care (how to prevent skin breakdown, manage waste and leaks, and reduce embarrassment from sounds and smells) can be beneficial in helping them adapt and minimize challenges. Healthcare providers can help mitigate patient anxiety about stomas by acknowledging that sexual health issues are common and educating their patients [49]. Women adjusting to living with an ostomy may experience issues of body image, concerns about interpersonal/intimate relationships, and possibly anxiety related to participating in physical/social activities, all of which can impact QOL [7, 26]. These women should be instructed to empty their pouches and check the seal of the appliance before engaging in sexual activity [7]. While an ostomy surgery does not directly affect sexual desire or function, women may worry about their partner's response or leakage of their pouch during intimacy [5]. Rehabilitation and support of ostomy patients are critical, and patients can benefit from appropriate counseling from healthcare providers.

Changes in body function after cancer treatment have been shown to impact the way survivors view themselves and interact with others [13, 14, 26, 31, 33]. Reintegrating into social relationships, including intimate relationships and friendships, can be challenging. The unpredictability of incontinence/bowel clustering can interfere with social activities, as bowel dysfunction is associated with social stigma and fear [50]. The ability to participate in life activities (such as sexual or intimate contact) is strongly associated with QOL among rectal cancer survivors and should be evaluated as a causal factor in reduced QOL [25]. The ability to participate in life activities (such as sexual or intimate contact) is strongly associated with OOL among rectal cancer survivors and should be evaluated as a causal factor in reduced QOL [25]. It was found that stoma-related gastrointestinal toxicity (as measured by the LENT/SOMA scale) is associated with poorer social functioning [33]. Also, since perceived social support has been shown to decline following a colorectal cancer diagnosis and treatment, assessing social support from initial diagnosis throughout survivorship can enable targeted interventions to improve health-related QOL [51]. Social support is an essential aspect of recovery, as high levels of social support show better health outcomes and health-related QOL after cancer treatment. Women of low socioeconomic

status who present with co-morbidities typically experience limited social support due to caregiver burden and decreased contact with providers in survivorship [51]. This is a crucial dichotomy for health providers to acknowledge when caring for this patient population. Benedict C. et al elaborates on the social/intimacy challenges post treatment for survivors and emphasizes dialogue on these topics as a crucial tool in managing survivorship [13]. Healthcare professionals can address this concern by initiating conversations about options for social support and intimacy from the time of initial diagnosis throughout survivorship follow-ups.

#### **Study Weaknesses**

Many studies examined the QOL of patients with colorectal/anal cancer; however, few explored the sexual health concerns specific to women with a history of such cancers. The studies we identified had small numbers of female patients. Small sample sizes can reduce statistical power and impact the generalizability of findings to all female patients/survivors of colorectal/anal cancer. For instance, Philip et al. surveyed a homogenous sample (without ethnic diversity) of patients receiving care at a large urban cancer center [25]. This cross-sectional survey study examined the characteristics of women enrolled in an intervention trial to treat sexual dysfunction and explore the relationship between sexual function and psychological wellbeing. Of those in the intervention trial, sexual dysfunction was significantly and consistently associated with psychological wellbeing. Even though the small homogenous sample limits the generalizability of the findings, this study explored an understudied clinical issue within cancer care. Small samples can be viewed as a weakness, but can also facilitate group comparison and provide important insights into rare malignancies.

Including patients at varying stages of post-treatment survivorship can serve as another limitation, as their needs may differ across the continuum of care. It can be misleading to compare patients at different stages of survivorship. For example, Philip et al. conducted a study with 70 women with anorectal cancer; however, all participants were at varying stages of post-treatment survivorship [25].

While retrospective cross-sectional survey studies are feasible and convenient methods to examine areas of interest [13–15, 17, 19–21, 24–26, 30–34], this study design is also subject to recall bias. The studies reported in this review used various PRO measures to assess aspects of QOL, including the EORTC-QLQ-C30 [21, 23, 25, 33], EORTC-QLQ-CR38 [13, 14, 20, 21, 24, 25, 32, 33], and the FSFI [13, 15–18, 23–28, 30, 31, 33, 34], but additional validated measures specific to sexual function are needed to understand the complexity of intimacy during and after colorectal/anal cancer treatment.

Although cross-sectional survey studies can give a snapshot of the patient experience, they are limited by their single timepoint assessment. Longitudinal measurement is needed to explain chronicity or transitive nature of changes. Cross-sectional studies are useful for providing descriptive analyses and generating hypotheses, yet this method is susceptible to potential sampling bias. To address the risk of self-report bias and poor retrospective recall, some researchers asked their patients about their pre-cancer levels of sexual function to

compare them to current levels [31, 32]. Overall, however, cross-sectional studies lack strength without the ability to understand conditions over time [28].

To ensure a more systematic approach to understanding the needs of patients across the continuum of care, more long-term follow-up designs with pre-treatment baselines are needed. Also, a lack of control groups [28] does not allow researchers to draw definitive conclusions. Patients may have had sexual health concerns before cancer, so without a pre-treatment assessment, it may be difficult to pinpoint the specific treatment-related contributing factors for the sexual health issues. Many women experience sexual dysfunction with age, including a lack of sexual desire and arousal, as well as poor vulvovaginal tissue quality, emphasizing the need for pre-treatment assessment and comparisons with general population norms.

Within this review, many studies had high response rates [13, 24, 30, 32], while others had low response rates [19, 31]. Of note, high response rates were seen when participants were asked to complete a questionnaire during a preoperative visit, ensuring completion of study materials. Traa et al. noted high levels of stress and discomfort with intimate questions as reasons for declining participation in their cross-sectional survey study [31]. Participants' willingness or unwillingness to discuss their sexual life may underestimate the concerns of this population. Data on why patients decline participation are needed. Future research studies should incorporate methods to elicit this information in ways that make the patient feel respected and comfortable.

#### **Study Strengths**

Recent intervention studies have provided important insights into the impact of treatment on the sexual function of patients with colorectal/anal cancer. Reese and colleagues used a flexible coping model in an intervention study focused on the sexual concerns of patients with colorectal cancer and their partners (n=18) [28]. The goal of this phone-based intervention was to aid couples in making cognitive and behavioral shifts in their relationship. The participants had four 50-minute sessions focused on couples coping skills, sex therapy, communication strategies and intimacy-building activities. The results suggested that telephone-based couple's interventions for this population are feasible and may enhance intimacy. The strengths of this study included the use of validated measures and access to a novel intervention.

Reese and Haythornthwaite looked at the importance of sexuality in terms of predictors, changes, and response to an intimacy enhancement intervention in patients with colorectal cancer [27]. This study noted several factors contributing to how an individual perceives sexuality, such as the presence of an intimate partner, being on active treatment, or having metastatic disease. Patients classified as sexually dysfunctional rated sexuality as less important and indicated sex was less important to them after cancer. The strengths of this intervention included its theory-driven approach and use of a validated sexual health measure, the FSFI.

Duhamel et al. conducted a randomized controlled trial to assess the efficacy of a telephone-based, four-session Cancer Survivorship Intervention-Sexual Health (CSI-SH) in women

with a history of rectal/anal cancer [23]. Participants (n=70) were randomized to CSI-SH or assessment-only and received four 1-hour individual sessions that included the following: (1) an overview of sexual health, (2) discussion of strategies to improve sexual functioning, (3) education on effective communication methods, and (4) provision of additional resources (i.e., educational booklets or relevant referrals). The results demonstrated improved sexual and psychological functioning and QOL in the women on the CSI-SH arm. This study highlights the importance of providing patients with sexual health education, support, and resources during survivorship care.

## Recent Clinical Findings of a Cohort of Survivors of Colorectal/Anal Cancer Who Sought Sexual Health Treatment

Patients consisted of women with a history of colon (n=9), rectal (n=49), or anal cancer (n=41) who sought sexual/vulvovaginal health care at the Female Sexual Medicine and Women's Health Program at Memorial Sloan Kettering Cancer Center [16]. Participants were diagnosed with cancer between 1989 and 2015. Mean age was 48 years (range, 18–77 years). On average, women were seen approximately 3 years from diagnosis (range, 9 months to 9.5 years). Demographic and medical characteristics are presented in Table 2.

Sixty-seven percent (n=56/83) reported symptoms of mild-severe vaginal dryness, 36% (n=30/84) mild-severe dyspareunia (VAS), and 60% (n=44/73) mild-severe vulvar dryness (VuAS) (Table 3). Upon gynecologic exam, 54% (n=30/56) had mild-severe vaginal atrophy, and 67% (n=44/66) experienced pain with an exam. Forty percent (n=21/54) had issues of fecal incontinence, 47% (n=27/58) had urinary incontinence, and 56% (n=32/57) were currently wearing a pad/panty liner. Thirty-three percent (n=29/88) were currently sexually active per the SAQ. The main reason for not engaging in sexual activity (as cited on the SAQ) was a physical issue making sexual activity difficult or uncomfortable (64%, n=38/59).

When queried about "How concerned are you about sexual/vaginal health?" (n=82), 91% (n=75) reported being somewhat to very concerned about this issue. Forty-eight percent (n=39/82) indicated a lack of confidence about future sexual activity. In all, 98% (n=88/90) scored <26.6 on the FSFI (mean, 10.5; median, 7.8), indicating female sexual dysfunction. The FSFI examined those who were and were not sexually active per the SAQ. Of those who were sexually active, 90% (n=27/29) scored <26.6 (mean, 16.32; median, 14.85). Of those who were not sexually active, 100% (n=59/59) scored <26.6 (mean, 7.36; median, 4.45). The mean FSFI score of those who were sexually active compared to those who were not sexually active varied greatly, highlighting the caution with this instrument (Figure 1).

Overall, women who sought treatment for sexual and vaginal health concerns after treatment for colorectal/anal cancer showed symptoms on a gynecologic exam that were in line with results on the PRO measures. Within this cohort, many had vulvovaginal tissue quality concerns and few were sexually active or confident about future sexual activity in survivorship. Throughout colorectal/anal cancer survivorship, many women experience persistent vaginal/sexual health concerns. Simple vulvovaginal health promotion strategies have been shown to provide symptom relief and promote intimacy [16] (Table 4).

Our study had limitations. The data were from women who sought treatment for sexual/vulvovaginal health issues. There are no data on survivors of colorectal/anal cancer who did not seek treatment. It is possible that our sample may be more symptomatic or motivated to address vulvovaginal health and intimacy concerns. Of note, our patients were much younger than the average age of patients with colorectal/anal cancer. Perhaps younger women are more motivated to seek treatment for these issues and may be an ideal risk group for interventions. Nevertheless, women of all ages need support, and providers should be encouraged to have discussions with their patients regarding vulvovaginal health and intimacy concerns, providing information and making referrals, as needed.

#### **Future Directions of Research and Clinical Care**

Studies that have examined the sexual function of women with colorectal/anal cancer have shown that sexual dysfunction is a prevalent issue after cancer treatment. Although the rates of sexual dysfunction vary by study design and treatment modality, research shows that the management of sexual function in patients with colorectal/anal cancer should be part of standard care. Furthermore, sexual function concerns should be re-assessed throughout treatment and into survivorship.

Future research should look to further validate measures, using larger sample sizes, and should focus specifically on female patients. Unlike with male sexual dysfunction, studies on female sexual dysfunction after colorectal/anal cancer are limited. This may reflect that female sexual dysfunction is multifaceted, complex [47–52], and not well understood. Female sexual function is challenging to measure due to dynamic and non-linear changes that take place over time when compared to male sexual function (e.g., erectile dysfunction). Until recently, few validated scoring items regarding female sexual dysfunction were available. Furthermore, male healthcare providers may be apprehensive or reluctant to speak with female patients regarding sexual function, as it is a sensitive topic [52].

Recent psychoeducational interventions have shown promising results [25, 27]. The intervention trial for couples conducted by Barsky-Reese and colleagues showed how these types of interventions may benefit this population by addressing symptoms and concerns [28]. One innovative approach is pre-rehabilitation, or "pre-hab." The essence of pre-hab is to reduce potential side effects of treatment before the treatment begins. Most research on pre-hab focuses on proper nutrition and exercise before treatment; however, in the realm of female sexual medicine, it could be beneficial to teach pelvic floor exercises, initiate moisturizer regimens for tissue quality, and advocate lubricant use with sexual activity before the initiation of treatment. Additionally, encouraging patients to seek support from medical professionals to reinforce realistic expectations may help reduce psychological distress post-treatment. Patients need access to high-quality information about the short- and long-term effects of cancer treatment. It is vital that as treatment modalities change, research follows suit.

Early intervention can consist of a comprehensive assessment of current concerns, education, and symptom management. Often in the cancer setting, oncologists are focused on controlling and curing the cancer, while side effects of treatment, including sexuality and intimacy issues, are relegated to other health professionals (e.g., social workers, primary care

providers) [53]. In evaluating sexual dysfunction, clinicians should be candid and direct in asking patients if they have any issues or changes with sex and intimacy. Normalizing concerns can be helpful and can be accomplished by reassuring patients that sexual issues after cancer treatment are common experiences. Standardized questionnaires can be used to screen for sexual function and can be given to patients before clinical appointments. The (VAS and VuAS are effective screens for tissue quality changes. The PROMIS measure has a validated 1-item sexual function screener that can be easily administered within a busy clinical setting [54]. The FSFI can help evaluate the specific sexual function concerns of desire, arousal, orgasm, vaginal dryness, and pain. Methods to assess sexual distress are also critical, such as with the Female Sexual Distress Scale (FSDS).

Simple vulvovaginal health promotion strategies and education can help mitigate patient concerns (Table 4); however, complex problems may require intervention with medical/ psychological therapies. Available treatments for sexual dysfunction in females are more limited than options for males. Common treatment suggestions include water or siliconebased lubricants during sexual activity, and vaginal moisturizers to alleviate vaginal and vulvar dryness. These products can make sexual intercourse and gynecologic exams more comfortable. Low-dose estrogens (vaginal) can also be used to relieve symptoms. Issues of pelvic floor dysfunction (e.g., painful sex, incontinence) after colorectal/anal cancer treatment are common. Pelvic floor muscle exercises can be helpful to enhance pelvic floor function and control. It is essential for women to learn how to relax the pelvic floor, especially in the setting of a history of pain, in addition to contraction [16, 55]. Pelvic floor dysfunction is common after pelvic surgery, contributing to pain (with exams and sex) and incontinence issues, also seen in our cohort. Pelvic floor physical therapy is an excellent resource to address these issues. It is also important to screen for chronic pad/pantyliner usage, as these may affect vulvar health by increasing vulvar dryness or trapping moisture. The types of pads/pantyliners that can provide optimal vulvovaginal support should be recommended, given that certain products, such as perfumed pads, can aggravate symptoms. Skin/tissue protectant creams, such as Aquaphor®, Balmex® or Desitin®, applied to the vulva can enhance comfort and protect the tissues from the drying and/or trapping effects of pads and/or external influences (urine or feces). Vaginal dilators can help prevent vaginal shortening and maintain vaginal elasticity [7], which can increase confidence and decrease anxiety over vaginal insertion discomfort.

#### **Conclusions**

A review of the existing literature shows that more research is needed to explore the sexual health concerns of women treated for colorectal/anal cancer with regard to long-term follow-up, pre-treatment assessments, and interventions. Future trials need to include more women and younger patients. Addressing the sexual health concerns of women with cancer is imperative for maximizing QOL into long-term survivorship. During the shared decision-making process, healthcare providers should prepare their patients to have clear, reasonable expectations from treatment and to be aware of the potential side effects of treatment, including sexual health side effects that may persist into survivorship.

Sexual health is often not addressed in survivorship care. As female survivors of colorectal/ anal cancer live longer, it is crucial to address post-treatment function for psychological wellbeing. A better understanding of the concerns of this patient population is pivotal in developing and implementing effective interventions. As healthcare providers, we should be proactive in identifying vulnerable patients and fostering symptom management, educational support, counseling, and referrals.

#### Acknowledgements

We would like to thank Sally Saban and George Monemvasitis for their careful review and feedback.

**Funding:** This study was funded in part through the NIH/NCI Memorial Sloan Kettering Cancer Center Support Grant P30 CA008748.

#### References

- [1]. American Society of Cancer. Cancer Treatment and Survivorship: Facts and Figures (2016–2017). Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2016-2017.pdf. Accessed September 21, 2018.
- [2]. Simon K Colorectal cancer development and advances in screening. Clin Interv Aging 2016;11:967–76. [PubMed: 27486317]
- [3]. Moscicki AB, Darragh TM, Berry-Lawhorn JM, Roberts JM, Khan MJ, Boardman LA, et al. Screening for Anal Cancer in Women. J Low Genit Tract Dis 2015;19:S27–42. [PubMed: 26103446]
- [4]. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30. [PubMed: 29313949]
- [5]. Albaugh JA, Tenfelde S, Hayden DM. Sexual Dysfunction and Intimacy for Ostomates. Clin Colon Rectal Surg 2017;30:201–6. [PubMed: 28684938]
- [6]. Incrocci L, Jensen PT. Pelvic radiotherapy and sexual function in men and women. J Sex Med 2013;10 Suppl 1:53–64. [PubMed: 23387912]
- [7]. Haggstrom DA, Cheung WY. Approach to the long-term survivor of colorectal cancer Available from: https://www.uptodate.com/contents/approach-to-the-long-term-survivor-of-colorectal-cancer/print 2018 Accessed September 14, 2018.
- [8]. Alberts SR, Citrin D, Schwartz D, Rodriguez-Bigas M. Colon, Rectal, and Anal Cancers Available from: http://www.cancernetwork.com/cancer-management/colon-rectal-and-anal-cancers 2016 Accessed July 14, 2018.
- [9]. Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010;76:1005–11. [PubMed: 19540058]
- [10]. Hendren SK, O'Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005;242:212–23. [PubMed: 16041212]
- [11]. Panjari M, Bell RJ, Burney S, Bell S, McMurrick PJ, Davis SR. Sexual function, incontinence, and wellbeing in women after rectal cancer--a review of the evidence. J Sex Med 2012;9:2749–58. [PubMed: 22905761]
- [12]. Sukhu T, Ross S, Coward RM. Urological survivorship issues among adolescent boys and young men who are cancer survivors. Sex Med Rev 2018;6:396–409. [PubMed: 29396283]
- [13]. Benedict C, Philip EJ, Baser RE, Carter J, Schuler TA, Jandorf L, et al. Body image and sexual function in women after treatment for anal and rectal cancer. Psychooncology 2016;25:316–23. [PubMed: 25974874]
- [14]. Benedict C, Rodriguez VM, Carter J, Temple L, Nelson C, DuHamel K. Investigation of body image as a mediator of the effects of bowel and GI symptoms on psychological distress in female

- survivors of rectal and anal cancer. Support Care Cancer 2016;24:1795–802. [PubMed: 26446699]
- [15]. Bohm G, Kirschner-Hermanns R, Decius A, Heussen N, Schumpelick V, Willis S. Anorectal, bladder, and sexual function in females following colorectal surgery for carcinoma. Int J Colorectal Dis 2008;23:893–900. [PubMed: 18535831]
- [16]. Carter J, Stabile C, Seidel B, Baser RE, Goldfarb S, Goldfrank DJ. Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors. J Cancer Surviv 2017;11:274–83. [PubMed: 27868156]
- [17]. Corte H, Lefevre JH, Dehnis N, Shields C, Chaouat M, Tiret E, et al. Female sexual function after abdominoperineal resection for squamous cell carcinoma of the anus and the specific influence of colpectomy and vertical rectus abdominis myocutaneous flap. Colorectal Dis 2011;13:774–8.
  [PubMed: 20402742]
- [18]. da Silva GM, Hull T, Roberts PL, Ruiz DE, Wexner SD, Weiss EG, et al. The effect of colorectal surgery in female sexual function, body image, self-esteem and general health: a prospective study. Ann Surg 2008;248:266–72. [PubMed: 18650637]
- [19]. Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 2010;116:822–9. [PubMed: 20041481]
- [20]. Den Oudsten BL, Traa MJ, Thong MS, Martijn H, De Hingh IH, Bosscha K, et al. Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. Eur J Cancer (Oxford, England: 1990) 2012;48:3161–70.
- [21]. Di Fabio F, Koller M, Nascimbeni R, Talarico C, Salerni B. Long-term outcome after colorectal cancer resection. Patients' self-reported quality of life, sexual dysfunction and surgeons' awareness of patients' needs. Tumori 2008;94:30–5. [PubMed: 18468332]
- [22]. Doeksen A, Gooszen JA, van Duijvendijk P, Tanis PJ, Bakx R, Slors JF, et al. Sexual and urinary functioning after rectal surgery: a prospective comparative study with a median follow-up of 8.5 years. Int J Colorectal Dis 2011;26:1549–57. [PubMed: 21922200]
- [23]. DuHamel K, Schuler T, Nelson C, Philip E, Temple L, Schover L, et al. The sexual health of female rectal and anal cancer survivors: results of a pilot randomized psycho-educational intervention trial. J Cancer Surviv 2016;10:553–63. [PubMed: 26667358]
- [24]. Milbury K, Cohen L, Jenkins R, Skibber JM, Schover LR. The association between psychosocial and medical factors with long-term sexual dysfunction after treatment for colorectal cancer. Support Care Cancer 2013;21:793–802. [PubMed: 22948439]
- [25]. Philip EJ, Nelson C, Temple L, Carter J, Schover L, Jennings S, et al. Psychological correlates of sexual dysfunction in female rectal and anal cancer survivors: analysis of baseline intervention data. J Sex Med 2013;10:2539–48. [PubMed: 23551928]
- [26]. Reese JB, Finan PH, Haythornthwaite JA, Kadan M, Regan KR, Herman JM, et al. Gastrointestinal ostomies and sexual outcomes: a comparison of colorectal cancer patients by ostomy status. Support Care Cancer 2014;22:461–8. [PubMed: 24091721]
- [27]. Reese JB, Haythornthwaite JA. Importance of sexuality in colorectal cancer: predictors, changes, and response to an intimacy enhancement intervention. Support Care Cancer 2016;24:4309–17. [PubMed: 27220648]
- [28]. Reese JB, Porter LS, Somers TJ, Keefe FJ. Pilot feasibility study of a telephone-based couples intervention for physical intimacy and sexual concerns in colorectal cancer. J Sex Marital Ther 2012;38:402–17. [PubMed: 22900623]
- [29]. Reese JB, Shelby RA, Keefe FJ, Porter LS, Abernethy AP. Sexual concerns in cancer patients: a comparison of GI and breast cancer patients. Support Care Cancer 2010;18:1179–89. [PubMed: 19777269]
- [30]. Segelman J, Martling A, Machado M, Holm T, Bergmark K, Floter Radestad A. Preoperative sexual function in women with rectal cancer. Eur J Surg Oncol 2013;39:1079–86. [PubMed: 23953232]
- [31]. Traa MJ, De Vries J, Roukema JA, Den Oudsten BL. The preoperative sexual functioning and quality of sexual life in colorectal cancer: a study among patients and their partners. J Sex Med 2012;9:3247–54. [PubMed: 23016986]

[32]. Traa MJ, Orsini RG, Den Oudsten BL, De Vries J, Roukema JA, Bosman SJ, et al. Measuring the health-related quality of life and sexual functioning of patients with rectal cancer: does type of treatment matter? Int J Cancer 2014;134:979–87. [PubMed: 23934989]

- [33]. Welzel G, Hagele V, Wenz F, Mai SK. Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. Strahlenther Onkol 2011;187:175–82. [PubMed: 21347639]
- [34]. Yu-Hua L Sexual dysfunction in women after low anterior resection. Clin Nurs Res 2014;23:216–26. [PubMed: 23508830]
- [35]. Zutshi M, Hull T, Shedda S, Lavery I, Hammel J. Gender differences in mortality, quality of life and function after restorative procedures for rectal cancer. Colorectal Dis 2013;15:66–73. [PubMed: 22564198]
- [36]. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76. [PubMed: 8433390]
- [37]. Sprangers MA, te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Eur J Cancer (Oxford, England: 1990) 1999;35:238–47.
- [38]. Baser RE, Li Y, Carter J. Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer 2012;118:4606–18. [PubMed: 22359250]
- [39]. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208. [PubMed: 10782451]
- [40]. Hawkins Y, Ussher J, Gilbert E, Perz J, Sandoval M, Sundquist K. Changes in sexuality and intimacy after the diagnosis and treatment of cancer: the experience of partners in a sexual relationship with a person with cancer. Cancer Nurs 2009;32:271–80. [PubMed: 19444088]
- [41]. Bentzen AG, Balteskard L, Wanderas EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol (Stockholm, Sweden) 2013;52:736–44.
- [42]. Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. Cancer Control 2010;17:44–51. [PubMed: 20010518]
- [43]. Reese JB, Handorf E, Haythornthwaite JA. Sexual quality of life, body image distress, and psychosocial outcomes in colorectal cancer: a longitudinal study. Support Care Cancer 2018.
- [44]. Temple LK, Wong WD, Minsky B. The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Radiat Oncol 2003;13:469–77. [PubMed: 14586835]
- [45]. Brotto LA, Yule M, Breckon E. Psychological interventions for the sexual sequelae of cancer: a review of the literature. J Cancer Surviv 2010;4:346–60. [PubMed: 20602188]
- [46]. Stabile C, Goldfarb S, Baser RE, Goldfrank DJ, Abu-Rustum NR, Dickler MN, et al. Sexual needs and educational intervention preferences for women with cancer. Breast Cancer Res Treat 2017;165:77–84. [PubMed: 28547655]
- [47]. Manderson L Boundary breaches: the body, sex and sexuality after stoma surgery. Soc Sci Med (1982) 2005;61:405–15.
- [48]. Park J, Neuman HB, Bennett AV, Polskin L, Phang PT, Wong WD, et al. Patient expectations of functional outcomes after rectal cancer surgery: a qualitative study. Diseases of the colon and rectum 2014;57:151–7. [PubMed: 24401875]
- [49]. Silva NM, Santos MAD, Rosado SR, Galvao CM, Sonobe HM. Psychological aspects of patients with intestinal stoma: integrative review. Rev Lat Am Enfermagem 2017;25:e2950. [PubMed: 29236836]
- [50]. McMullen C, Liu L, Bulkley JE, Hornbrook MC, Wendel C, Grant M, et al. Participation in Activities Associated With Quality of Life for Long-Term Survivors of Rectal Cancer. Perm J 2017:21.
- [51]. Haviland J, Sodergren S, Calman L, Corner J, Din A, Fenlon D, et al. Social support following diagnosis and treatment for colorectal cancer and associations with health-related quality of life:

- Results from the UK ColoREctal Wellbeing (CREW) cohort study. Psychooncology 2017;26:2276–84. [PubMed: 29094430]
- [52]. Breukink SO, Wouda JC, Van Der Werf-Eldering MJ, Van De Wiel HBM, Bouma EMC, Pierie JP, et al. Psychophysiological assessment of sexual function in women after radiotherapy and total mesorectal excision for rectal cancer: a pilot study on four patients. J Sex Med 2009;6:1045–53. [PubMed: 18761589]
- [53]. Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. Fertil Steril 2013;100:916–21.
  [PubMed: 24011609]
- [54]. Flynn KE, Lindau ST, Lin L, Reese JB, Jeffery DD, Carter J, Baron SR, Abramsohn E, Weinfurt KP. Development and Validation of a Single-Item Screener for Self-Reporting Sexual Problems in US Adults. J Gen Intern Med 2015 4 18
- [55]. Faubion SS, Shuster LT, Bharucha AE. Recognition and management of nonrelaxing pelvic floor dysfunction. Mayo Clin Proc 2012;87:187–93. [PubMed: 22305030]

## FSFI and Sexual Activity Questionnaire (SAQ)

### FSFI Total score (n=90)

# Sexually Active as per SAQ (33%, n=29/88)

# Not Sexually Active as per SAQ (67%, N=59/88)

FSFI Mean: 10.5

• FSFI Median: 7.8

98% (88/90) <26.6</li>

FSFI Mean: 16.32


FSFI Median: 14.85


• 90% (27/29) <26.6


FSFI Mean: 7.36

FSFI Median: 4.45

100% (59/59) <26.6</li>









**Figure 1.**Female Sexual Function Index (FSFI) and Sexual Activity Questionnaire (SAQ) Results

Table 1.

#### Literature Review

Study	Sample	Study Design/Aim	Measures	Key Sexuality Results	Strengths	Limitations
Traa et al. 2014 [32]	n=439; nonadvanced disease (80), locally advanced rectal cancer (292), locally recurrent rectal cancer (67) (men and women)	Cross-sectional study to compare the HR-QOL of 3 patient populations with a focus on sexual functioning, and to compare to a normative population	Participants completed the following questionnaires: EORTC general HR-QOL questionnaire (QLQ-C30), disease specific EORTC- colorectal 38 (QLQ-CR38)	Patients with more extensive disease reported lower HR-QOL. Greater than 50% of women were sexually active before treatment and <35% after treatment. All groups reported lower sexual functioning scores compared to a normative population.	High response rate (85%); only study of HR-QOL with 3 types of rectal cancer populations; comparison to a normative population; validated/ reliable questionnaires	Cross-sectional design; no information on patients' functioning before treatment; QLQ- CR38 only asks 5 questions on sexuality
Benedict et al. 2016 [13]	n=70 anorectal cancer (women only)	Cross-sectional survey study seeking to describe body image problems, including sociodemographic and disease/ treatment correlates and examine relations between body image and sexual function	Participants completed the following questionnaires as part of a baseline assessment from sexual health intervention study: EORTC- QLQ-CR38 (Body Image subscale), FSFI	Body image is a potentially modifiable target to address sexual difficulties. Poor body image is inversely related to all aspects of sexual function, except pain. Strongest Association between FSFI sexual/ relationship satisfaction.	Importance of addressing sexual concerns in women who are not sexually active; near complete response rate for FSFI	Women agreeing to participate in a sexual health intervention study; cross-sectional design
Welzel et al. 2010 [33]	n=88 anal cancer (men and women)	Cross-sectional survey study to assess self-reported long-term QOL experienced by anal cancer patients after radiochemotherapy and identify patient and disease-related factors associated with QOL	Participants completed the following questionnaires: Cancer-specific QOL: EORTC QLQ-C30; Colorectal cancer module QLQ-CR38	Female sexual dysfunction is among the most frequently reported symptoms and was affected by marital status and radiotherapy dose (>50.4 Gy); 27% of females had engaged in sexual activity in past 4 weeks.	Rare cancer and limited research on anal cancer	Small sample size, which limited power size; retrospective nature
Segelman et al. 2013 [30]	n=82 rectal (women only)	Cross-sectional survey study to describe preoperative sexual functioning in a large group of women with rectal cancer	Participants completed the following questionnaire during a preoperative outpatient visit: FSFI	Sexual dysfunction and sexual inactivity are common in women with rectal cancer demonstrated by low FSFI scores.	Use of validated questionnaire; evaluation of preoperative functioning; high response rate (70%)	Recall bias may have influenced FSFI results; selection bias (non-Swedish- speaking women not included)
Traa et al. 2012 [31]	n=242; colorectal patients (136); partners of the patients (106) (men and women)	Cross-sectional survey study to describe preoperative sexual functioning, QOL, and relationship functioning of colorectal patients and their partners.	Participants completed the following questionnaires at home before their scheduled surgery for colorectal cancer: IIEF, FSFI, Golombok-Rust Inventory of Sexual Satisfaction, Maudsley Marital Questionnaire	Female patients had lower QOL than male patients. All patients and partners reported lower sexual functioning and lower QOL than a normative population but similar relationship functioning. The study highlights that colorectal patients may already experience low sexual functioning and quality of sex life before surgical treatment, showing surgical intervention may not be solely	Use of validated and comprehensive measures; in- depth view of preoperative sexual functioning, QOL and relationship functioning in patients and partners of both sexes	Patients completed assessments after diagnosis, so no statements can be made about functioning or sex life prior to diagnosis; time between diagnosis and completing questionnaires varied; one important reason for declining participation was high levels of stress and the intimate questions, perhaps underestimating

Study Study Design/Aim Strengths Limitations Sample Measures **Key Sexuality Results** responsible for high the concerns of sexual dysfunction. this population Bohm et n=26; colon Cross-sectional Participants Worse sexual Unable to compare Comparative al. 2008 pre- and (11) and rectal survey study to completed the functioning in the total group of patients [15] establish the postoperative (15); all had following mesorectal excision transabdominal incidence of questionnaires: group compared to the undergoing results rectal resection potential 'general control group surgery during (women only) postoperative questionnaire," the same time anorectal, bladder Wexner and sexual questionnaire, dysfunction in King's Health women after total Questionnaire, mesorectal excision **FSFI** compared to colonic resection (control group) n=80 anal Mean MOS Sexual Das et al. Cross-sectional Participants Squamous cell Small sample; 2010 cancer (men survey study to completed the Problems Scale score cancer of the 40% response rate; [19] and women) evaluate long-term following was 51 (out of 100) in a anal canal is a unable to account QOL in patients questionnaires relatively young sample for baseline sexual treated with at home: FACT-(median, 51) malignancy; function; crossdefinitive C, MOS Sexual supported the sectional design radiotherapy or Problems Scale need for more chemoradiation for modern squamous cell radiation cancer of the anal techniques to canal reduce toxicity from radiotherapy n= 47 anal Corte et Cross-sectional Participants 76% of women who Homogenous Small sample; low al. 2011 cancer (women survey study to completed the had an active sex life group regarding response rate; use [17] only) evaluate sexual life following before surgical of one questionnaire: of women after abdominoperineal technique, questionnaire surgery for **FSFI** resection still had which squamous cel intercourse after facilitates carcinoma of anus surgery. Colpectomy comparison (abdominoperineal reduces sex life. resection) Participants n=70 rectal and Benedict Long-term bowel and Insight into Cross-sectional Cross-sectional gastrointestinal et al. anal (women survey study to completed the how body design; small 2016 only) evaluate the degree following dysfunction are image sample; primary distressing and affect [14] to which bowel and questionnaires perception can focus prevented Gastrointestinal as part of a how women perceive exacerbate inclusion of dysfunction related baseline and relate to their body. other treatment covariates (history to psychological assessment from side effects distress in women sexual health psychopathology); treated for rectal or intervention participants were anal cancer. study: EORTCin an intervention Additionally, to QLQ-CR38 study for sexual examine whether (Diarrhea, health and may not body image Gastrointestinal represent other mediated the effect rectal/anal cancer Symptoms and of bowel and Body Image survivors subscales), Brief gastrointestinal dysfunction on Symptom Index psychological (depression and distress anxiety subscales) Philip et n=70 anorectal Cross-sectional Participants Of those in an Explored an Homogenous al. 2013 (women only) survey study to completed the intervention trial, understudied sample of ethnicity [25] examine the following sexual dysfunction was clinical issue and all received characteristics of questionnaires: significantly and within cancer care at a large women enrolled in ÊORTC-QLQconsistently associated cancer center; C30, QLQan intervention trial with measure of participants were CR38, FSFI, to treat sexual psychological at varying stages BSI-18, IES-R, dysfunction and wellbeing. of posttreatment explore the CR-38 Body survivorship; no relationship data on ageimage matched controls; between sexual functioning and no information on

Study	Sample	Study Design/Aim	Measures	Key Sexuality Results	Strengths	Limitations
		psychological wellbeing				the sexual functioning of patients' partners
Di Fabio et al. 2008 [21]	n=62 colorectal patients (men and women)	Cross-sectional survey study to explore aspects of QOL in long-term survivors (including sexual dysfunction) and surgeons' awareness of patients' needs to determine how to improve follow-up care programs	Participants completed the following questionnaires: EORTC QLQ- C30, QLQ-C38, postoperative sexual problems evaluated with 6 items	61% colon patients and 24% rectal patients reported no sexual problems. Patients who reported no sexual problems had better QOL.	QOL measures can help detect problems that may go unnoticed in routine followup care; novel study of perception mismatch between doctors and patients; studies like this help to reduce long-term postoperative dissatisfaction	Small sample; single-center setting; cross- sectional design
Den Oudsten et al. 2012 [20]	n=1759; colon and rectal survivors (1359) and normative population (400) (men and women)	Cross-sectional survey study to explore the prevalence of erectile dysfunction, ejaculation problems, dyspareunia, and dry vagina in colon and recall cancer survivors and a normative population. Additionally, to compare dysfunction between groups and describe the sociodemographic, clinical and psychological correlates of sexual dysfunction in survivors	Participants completed the following questionnaires: SCQ, EORTC, QLQ-CR38, FAS, HADS	Vaginal dryness was common in colon (28%) and rectal (35%) cancer survivors. Colon and rectal cancer survivors experienced more pain with intercourse than a normative population	Inclusion of a normative population contributed to debate on whether sexual dysfunction in a higher age is normal or pathological; high response rate	Cross-sectional; no information on sexual functioning before cancer treatment/ diagnosis; EORTC QLQ-CR-38 provides limited information on sexual functioning
Milbury et al. 2013 [24]	n=261 colorectal (144 male and 117 female)	Cross-sectional survey study to identify demographic, medical, and psychosocial risk factors to explain a proportion of the variance in male and female sexual function in colorectal cancer survivors	Participants completed the following questionnaires in clinic or at home: IIEF, FSFI, EORTC- QLQ-CR38, CES-D, BSI-18, MOS-SSS, A- DAS	Patients' age and more destructive procedures are related to poor sexual function	Helped to identify patients at high risk for sexual dysfunction after cancer treatment; inclusive of sexually inactive survivors; high response rate for clinic follow-up (90%)	Cross-sectional; no pre-treatment assessment; low power (small sample because the rarity of abdominoperineal resection); homogenous sample; potential sampling bias from different recruitment methods
Yu-Hua et al. 2014 [34]	n=64 rectal (32 with low anterior resection and 32 healthy women) (women only)	Cross-sectional survey study to investigate the prevalence of sexual functioning problems among women who have had a low anterior resection	Participants completed the following questionnaires: FSFI	Women who have had a low anterior resection are at higher risk of sexual function problems; FSFI domain scores lower for the low anterior resection group compared to healthy women	Insight into the sexual dysfunction experienced by Taiwanese women following low anterior resection	Cross-sectional design (no causality inference); selection bias (healthy women recruited from women known to researcher); did not expand to

Study Study Design/Aim **Key Sexuality Results** Strengths Limitations Sample Measures other relevant parameters (hormonal status, previous sexual experience or spousal attitude) Reese et al. 2014 n=141 Use of Cross-sectional Participants Current and past Cross-sectional colorectal (18 survey study where completed the ostomy groups had validated and design (limits post ostomy; [26] data were collected following worse sexual comprehensive generalizability 25 current from a larger questionnaires: functioning and body measures; and no causal ostomies; and prospective study Medical Impact image than the no prospective interpretations); 98 no ostomy) examining physical on Sexual study design uneven groups; ostomy group (men and and emotional Function, FSFI, low response rate predictors of sexual IIEF, Body for women women) QOL in colorectal Image Scale, answering sexual patients. The aim CES-D function questions was to compare colorectal cancer patients by ostomy classification group with respect to sexual function, perceived impact of disease, and treatment on sexual function and body image distress n=141 Intervention study Participants Perceived importance Theory-driven Use of two single Reese et al. 2016 colorectal to examine the completed the of sexuality decreased approach;, use items (non-[27] importance of following for individuals treated of validated validated) to assess cancer (men sexuality within the questionnaires and women) for colorectal cancer measures; importance of self-view and crossas part of a and can increase inference of sexuality; some sectional through participating in larger causality comparisons on correlations. To prospective an intimacy-focused (secondary small subsamples determine if the study examining analyses of not allowing for intervention. importance of physical and outcomes from testing of sexuality changes emotional an intervention longitudinal predictors of after participating hypotheses study) sexual QOL in in an intimacy colorectal enhancement intervention patients: 2 importance of sexuality items, ESFL HEF: participants were randomized to an intimacy enhancement condition (intervention) DuHamel n=70 rectal and Intervention trial to Participants This study Pilot study and Improved sexual and provided anal cancer assess the efficacy psychological represents small et al. randomized to functioning and QOL in the CSI-SH group. preliminary 2016 assessment only of a telephonesample of survivors [23] (women only) or CSI-SH and data to inform based, four-session survivors: and develop a inclusion criteria cancer survivorship completed the The intervention was telephone-based were limited to intervention for more efficacious for larger Intervention intervention rectal and anal sexually active women. women who trial for sexual reported low to and/or cancer survivors assessments at dysfunction and moderate degrees baseline, 4 mo. OOL of satisfaction; and 8 mo. FSFI, challenging IES-R, BSI, recruitment; EORTC-QLQheterogenous C30 sample Carter et n=175; Longitudinal Participants After two visits to the Simple Only included al. 2017 [16] completed the women with colorectal/anal intervention study program, participants strategies can (15), breast (baseline and 1 be helpful to follow-up; following showed improvement questionnaires: potential subject follow-up) to (90).in vulvar/vaginal women treated gynecologic evaluate patient VAS, VuAS, symptoms, enhanced for cancer: bias to self-report

Study	Sample	Study Design/Aim	Measures	Key Sexuality Results	Strengths	Limitations
	(54), other (16) (women only)	adherence and response to vaginal and sexual health treatment strategies in a female sexual medicine and women's health program.	FSFI, SAQ, SSS; all patients had two gynecologic exams (pelvic exam checklist)	sexual function, increased sexual activity and confidence in sexual activity, decline in elevated vaginal pH, and decreased pain with gynecologic exam.	intervention that has substantial clinical relevance (evaluation of emotion and physical implications of changes to vulvovaginal health and sexual functioning in women with cancer)	measures; absence of a control group
da Silva et al. 2008 [18]	n=93; colon (57) and rectal (36) (women only)	Longitudinal survey study to evaluate women's sexual function, self- esteem, body image and health-related QOL after colorectal surgery	Participants completed the following questionnaires preoperatively, 5 and 12 months postoperatively: FSFI, Rosenburg Sel- Esteem Scale, Body Image scale, SF-36	Significant deterioration of sexual function 6 Months postoperatively with partial recovery at 12 months. 81% stated that it was somewhat- extremely important to discuss sexual issues.	Validated questionnaires; longitudinal design	Low response rate to FSFI; use of one questionnaire
Doeksen et al. 2011 [22]	n=136; underwent rectal resection (83) or colonic resection leaving rectum in situ (53) (men and women)	Longitudinal survey study (preoperatively, 3 mo., 12 mo., 8 years) to prospectively compare long-term sexual and urinary function between patients who underwent rectal resection and a control group (hemicolectomy, subtotal colectomy or ileocolic resection). Bowel function and QOL were secondary endpoints.	The following questionnaires were sent to participants to complete at home: items assessing sexual, urinary and bowel functioning with a QOL questionnaire (SF-36)	Patients who underwent rectal resection experienced more sexual and bowel function issues than rectum in situ patients up to 1 year postoperatively.	Longitudinal study from preop to 8.5 years postop	Small sample; heterogenous population
Reese et al. 2010 [29]	n=113; colon or rectal (56) and anal (1) (men and women)	Longitudinal survey study to assess sexual concerns in gastrointestinal cancer patients compared with breast cancer patients. Also examined if sexual concerns change over time and evaluated whether sexual concerns are significantly associated with functioning in other domains (QOL, symptom severity, disease interference, disease-related distress)	Participants completed the following questionnaires during 4 outpatient clinic visits over 6 months: Sexual concerns (reduced sexual enjoyment, interest or performance), quality of life (FACT-G), symptom severity, disease interference (MD Anderson Symptom Inventory), disease-related	Sexual concerns were common in 57% of the gastrointestinal patients. Concerns were stable over time and significantly associated with lower levels of functioning in QOL, symptom severity, disease interference, and disease-related distress.	Prospective design with multiple timepoints; validated instruments to measure perceived disease impact and QOL; large sample	Single item to assess sexual concerns (not validated); subjective nature of sexual concern item; brief timespan (6 months); lack of information on type of treatment received

al. 2018

[29]

and rectal

(men and

women)

cancer patients

Study Study Design/Aim **Key Sexuality Results** Strengths Limitations Sample Measures distress (NCCN Distress Scale) Zutshi et n=260 rectal Longitudinal survey Sexual function Only 4 items to Participants Prospective al. 2012 completed the declined sharply within cancer (male study to assess the observation assess sexual effect of rectal the first year after [35] and female) function in women following over 5 years questionnaires surgery and gradually cancer treatment on bowel function. over 5 years (3 over 5 years. OOL, and sexual mo., 6 mo., 1 activity year, 3 years, 5 years): SF-36, CGQOL, QOL questions, Kirwan score, Sexual function questions (validated) n=14 couples Limited Reese et Pilot study to Participants The majority rated the Comprehensive al. 2012 [28] collect preliminary completed four generalizability (men and intervention as at least "quite a bit" helpful set of outcome and feasibility women) data on the 50-minute because of small feasibility and phone-based sample size and overall, easy to measures; participate in, and as an efficacy of an intimacy grounding in lack of control intervention for enhancement important program for empirically group, so unable to physical intimacy intervention people with colorectal supportive draw definitive and sexual concerns sessions. cancer. cognitive and conclusions on Additionally, in colorectal cancer behavioral efficacy of the participants studies; test of intervention; no completed the a novel long-term following intervention; followup questionnaires: implemented use of skills strategy to questions, overcome recruitment program challenges, evaluation questions, Index such as of Sexual telephone-Satisfaction, based format FSFI, IIEF, that eliminated Dyadic Sexual participant Communication travel burden Scale, Miller Social Intimacy Scale, Dyadic Adjustment Scale Bentzen n=128 anal Cross-sectional EORTC QLQ-Statistically significant Large sample Single items to CR29 assesses cohort study with difference between anal of female anal et al., cancer (male assess sexual 2013 and female) Norwegian national sexual interest cancer survivors and cancer interest and survivors, with [41] registry and dyspareunia matched volunteers dyspareunia and sexual function. Anal 64% response only at one time cancer patients had rate; point decreased sexual comparison interest (p<0.0001) and with Dutch and greater dyspareunia Norwegian (p<0.0001). normative data Reese et n=141 colon Longitudinal mail-Sexual Distress 73.8% of women Assessment of Mixed sample of

Page 21

EORTC, European Organization for Research and Treatment of Cancer; HR-QOL, health-related quality of life; FSFI, Female Sexual Function Index; IIEF, International Index of Erectile Functioning; FACT-C, Functional Assessment of Cancer Therapy-Colorectal; MOS, Medical Outcomes Study; BSI, Brief Syndrome Inventory; IES-R, Impact of Event Scale-Revised; SCQ, Self-administered Comorbidity Questionnaire; FAS, Fatigue

experienced sexual

dysfunction (as per

body image were

compromised after

colorectal cancer and

remained over time.

FSFI). Sexual QOL and

multiple

domains of

assessment

sexual QOL; 2

points over time

patients actively

post-treatment;

mean time since

months;

homogenous

sample (race/ ethnicity); predominantly male participants

treatment was 31.5

on treatment and

Scale (ISS),

SFQ, (FSFI

based survey with 2

assessment points -

study enrollment

(baseline) and 6

months follow-up.

Assessment Scale; HADS, Hospital Anxiety and Depression Scale; CES-D, Center for Epidemiological Studies-Depression; MOS-SSS, Medical Outcomes Study Social Support Survey; A-DAS, Abbreviated Dyadic Adjustment Scale; CSI-SH, Cancer Survivor Intervention--Sexual Health; SF-36, Short Form Health Survey-36; SFQ, Sexual Function Questionnaire

Table 2.

### Demographic and Medical Characteristics

Basic Demographics (N=99)				
	n	%		
Disease Site				
Colon	9	9%		
Rectal	49	50%		
Anal	41	41%		
Age at diagnosis				
Colon	40 (range, 24–55)			
Rectal	46 (range, 18–77)			
Anal	53 (range, 38–69)			
Race	•	•		
White	88	89%		
Black	5	5%		
Asian	3	3%		
Other/Unknown	3	3%		
Marital Status	•	•		
Married	64	65%		
Single	19	19%		
Divorced/Widowed/Separated	17	16%		
Engage in Sexual Activity (n= 88)				
Yes	29	33%		
No	59	67%		
Date of Diagnosis				
1989–2000	3	3%		
2001–2009	26	26%		
2010–2015	70	71%		
Time from diagnosis to initial consult				
3 months – 1 year	54	55%		
2 years – 9 years	37	37%		
10 years – 25 years	8	8%		
Age at initial consult (mean, 48 yrs; range, 20–78 yrs)				
20–39	6	6%		
40–50	42	43%		
51–60	38	38%		
61–78	13	13%		
Treated with radiation				
Yes	94	95%		
No	6	5%		

Table 3.

Vaginal Assessment Scale (VAS) and Vulvar Assessment Scale (VuAS)

VAS (N=99)	None	Mild	Moderate	Severe
Dryness	27% (27)	20% (20)	11% (11)	25% (25)
Soreness	66% (65)	7% (7)	8% (8)	2% (2)
Irritation	68% (67)	10% (10)	2% (2)	2% (2)
VuAS (N=99)	None	Mild	Moderate	Severe
i				
Dryness	29% (29)	16% (16)	15% (15)	13% (13)
Dryness Soreness	29% (29) 46% (46)	16% (16) 13% (13)	15% (15) 9% (9)	

#### Table 4.

#### Vulvovaginal Health Promotion Strategies

Strategy	Purpose	Recommendation
Vaginal moisturizers Ex. Hydrating Moisturizers Replens ®HyaloGYN ®	Manage vaginal and vulvar dryness and improve tissue quality by increasing moisture and elasticity of the tissues	Use 3–5 times per week Apply before bedtime Can be used in the vagina and on external (vulvar) tissues
Vaginal lubricants Ex. Water-based – Astroglide, KY, Yes, Luvena, Good Clean Love Silicone – Pjur, Astroglide silicone, Pink Natural Oils Coconut or almond oil	Used to add to natural lubrication and minimize discomfort with sexual touch and/or vaginal insertion	Use silicone- or water-based lubricants Apply with all sexual activity Avoid petroleum jelly, colored, flavored or warming lubricants that may cause irritation
Skin/Tissue Protectants Ex. Aquaphor®, Balmex® or Desitin®	Pads/panty liners can be very drying to the vulvar tissues Apply a skin/tissue protectant to protect the skin and help seal in moisture	Before using a pad/pantyliner apply the protectant cream to the external (vulvar) tissues
Pelvic floor muscle exercises	To strengthen pelvic floor muscles and prevent physical problems (incontinence) and improve sexual health and pleasure Kegels can relax vaginal muscles, improve arousal/blood circulation, and increase vaginal tone and lubrication	Perform pelvic floor exercises daily During each session, pull up and contract pelvic floor muscles for 3–6 seconds; and equal time to fully relax the pelvic floor for 3–6 seconds Repeat till muscle fatigue
Vaginal dilators	Vaginal dilators can help with comfort with exam, prevent the vagina from becoming too narrow, maintain vaginal elasticity, and reduce discomfort with sexual activity	Practice dilator therapy several times per week (every other day) Gradually increase the size of dilators without discomfort